| Clemson Sports Medicine And Rehabilitation Inc | |
|
10626 Clemson Blvd, Seneca, SC 29678-4526 | |
| (864) 482-0064 | |
| (864) 482-0074 |
| Full Name | Clemson Sports Medicine And Rehabilitation Inc |
|---|---|
| Type | Facility |
| Speciality | Rehabilitation Unit |
| Location | 10626 Clemson Blvd, Seneca, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275530503 | NPI | - | NPPES |
| 5092260001 | Other | SC | DMERC |
| Mailing Address | Practice Location Address |
|---|---|
| Clemson Sports Medicine And Rehabilitation Inc Po Box 1844, Clemson, SC 29633-1844 Ph: (864) 482-0064 | Clemson Sports Medicine And Rehabilitation Inc 10626 Clemson Blvd, Seneca, SC 29678-4526 Ph: (864) 482-0064 |
News Archive
Rakesh Pilkar, Ph.D., a post-doctoral fellow in Human Performance and Engineering Research at Kessler Foundation, was awarded a R03, $153,000 grant by the National Institutes of Health to study the response levels to function electrical stimulation (FES) interventions in the rehabilitation of stroke patients-titled, "Identification of Responders to the FES Interventions in Stroke Populations".
Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.
People with prosopagnosia, or "face blindness," have trouble recognizing faces - even those of close friends and family members.
A new study deals with the effect of two widely used vaccines in eliciting humoral immunity against the virus in this group. These are the Oxford/AstraZeneca viral-vectored vaccine (ChAdOx1 nCoV-19), and the Pfizer/BioNTech's messenger RNA-based vaccine (BNT162b2). Both express the viral spike antigen, and both are currently being employed in the UK's vaccination program.
› Verified 8 days ago